[Localized prostate cancer]. / Das lokalisierte Prostatakarzinom.
Pathologe
; 42(6): 603-616, 2021 Nov.
Article
en De
| MEDLINE
| ID: mdl-34648048
ABSTRACT
Prostate cancer is the most prevalent noncutaneous cancer in men. The Gleason grading is considered to be the strongest prognostic parameter regarding progression-free survival and overall survival. The original grading system has been modified during the last decade resulting in a more precise prognostic tool. The pretreatment Gleason score guides clinical management and is a key component in S3 guidelines for prostate cancer. In addition to Gleason score several other histologic findings in prostate needle biopsy influence patient management. In this second part of our CME series about prostate cancer, we will discuss the diagnosis of prostate cancer and current guidelines for reporting prostate cancer. In addition, we will highlight prostate lesions of urothelial origin and neuroendocrine prostate cancer as well as prognostic biomarkers.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
Tipo de estudio:
Guideline
/
Prognostic_studies
Idioma:
De
Revista:
Pathologe
Año:
2021
Tipo del documento:
Article